AZ重金押注AAV基因疗法、默沙东百亿美元买K药替补、诺华看上血脑屏障穿透技术 | BD交易

新浪医药07-10

刚过去的两天内，诸多跨国药企公布了其最新交易。诺华与维泰瑞隆（Sironax ）就后者的跨脑递送平台达成交易；阿斯利康与合作伙伴JCR Pharmaceuticals就一项基因药物达成协议；默沙东以100亿美元收购Verona Pharma的慢性阻塞性肺病（COPD）药物Ohtuvayre。诺华 & 维泰瑞隆美东时间7月9日，诺华与生物科技公司Sironax（维泰瑞隆）达成协议，获后者专有的“脑部...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2550464047?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-10 19:29","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2550464047","market":"us","top_or_hot":-1,"title":"AZ重金押注AAV基因疗法、默沙东百亿美元买K药替补、诺华看上血脑屏障穿透技术 | BD交易","media":"新浪医药","content":"<div>\n<p>刚过去的两天内，诸多跨国药企公布了其最新交易。诺华与维泰瑞隆（Sironax ）就后者的跨脑递送平台达成交易；阿斯利康与合作伙伴JCR Pharmaceuticals就一项基因药物达成协议；默沙东以100亿美元收购Verona Pharma的慢性阻塞性肺病（COPD）药物Ohtuvayre。诺华 & 维泰瑞隆美东时间7月9日，诺华与生物科技公司Sironax（维泰瑞隆）达成协议，获后者专有的“脑部...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710201226a6a19e54&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AZ重金押注AAV基因疗法、默沙东百亿美元买K药替补、诺华看上血脑屏障穿透技术 | BD交易</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAZ重金押注AAV基因疗法、默沙东百亿美元买K药替补、诺华看上血脑屏障穿透技术 | BD交易\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-10 19:29 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710201226a6a19e54&s=b><strong>新浪医药</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>刚过去的两天内，诸多跨国药企公布了其最新交易。诺华与维泰瑞隆（Sironax ）就后者的跨脑递送平台达成交易；阿斯利康与合作伙伴JCR Pharmaceuticals就一项基因药物达成协议；默沙东以100亿美元收购Verona Pharma的慢性阻塞性肺病（COPD）药物Ohtuvayre。诺华 & 维泰瑞隆美东时间7月9日，诺华与生物科技公司Sironax（维泰瑞隆）达成协议，获后者专有的“脑部...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710201226a6a19e54&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999013999.USD","symbol_name":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710201226a6a19e54&s=b","article_id":"2550464047","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710201226a6a19e54&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2550464047","pubTimestamp":1752146990,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"诺华声明中指出，血脑屏障穿透是药物研发的关键挑战，此次合作将利用诺华在神经科学领域的专长开发下一代疗法。根据协议，Alexion可在最多五个基因组药物项目中使用这些衣壳。Ohtuvayre于2023年6月获FDA批准作为COPD维持治疗药物；2024年第一季度，Verona估计其处方量约2.5万份，销售额达7130万美元。Ohtuvayre将强化默沙东的呼吸道产品组合，后者近期还获批呼吸道合胞病毒抗体药物Enflonsia。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0861579265.USD":"联博低波幅策略股票基金A","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","BK4578":"CAR-T","MRK":"默沙东","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0058720904.USD":"联博国际健康护理基金A","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU1035773651.USD":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (USD) INC","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","BK4588":"碎股","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU1037948897.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (HKD) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","NVS":"诺华","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","LU1917777945.USD":"安联专题基金Cl AT Acc","AZ":"A2Z Cust2Mate Solutions Corp","SG9999002232.USD":"Allianz Global High Payout USD","LU1037948541.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (HKD) ACC","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","LU1116320737.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (USD) INC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU0265550946.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A5\" (USD) INC","LU1934455863.HKD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (HKD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","SG9999014542.SGD":"United Income Focus Trust Acc SGD","BK4585":"ETF&股票定投概念","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC"},"translate_title":"AZ is betting heavily on AAV gene therapy, Merck buys K drug substitutes for tens of billions of dollars, Novartis is interested in BD transactions for blood-brain barrier penetration technology","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRK":1,"AZ":1,"NVS":1},"content_text":"刚过去的两天内，诸多跨国药企公布了其最新交易。诺华与维泰瑞隆（Sironax ）就后者的跨脑递送平台达成交易；阿斯利康与合作伙伴JCR Pharmaceuticals就一项基因药物达成协议；默沙东以100亿美元收购Verona Pharma的慢性阻塞性肺病（COPD）药物Ohtuvayre。诺华 & 维泰瑞隆美东时间7月9日，诺华与生物科技公司Sironax（维泰瑞隆）达成协议，获后者专有的“脑部递送模组（Brain Delivery Module,BDM）”平台。该平台是一种差异化的血脑屏障穿透技术，旨在提高多种形式药物的脑部递送效率。根据协议，诺华可在试用期后决定是否收购该平台；若收购，Sironax可能获得最高1.75亿美元的预付款和近期付款。Sironax保留继续开发使用该脑部递送模块平台的未命名管线项目的权利。该平台旨在通过多种方式改善药物向大脑的递送效率。Sironax作为一家处于临床阶段的生物科技公司，主要资产包括两款RIPK1抑制剂：SIR9900用于神经退行性疾病，SIR2446用于免疫/炎症疾病，均处于1a期测试阶段。Sironax在美中两地运营，由百济神州联合创始人王晓东于2018年创立，聚焦衰老相关疾病治疗；2022年，其B轮融资2亿美元，投资者包括F-Prime Capital和ARCH Ventures。诺华声明中指出，血脑屏障穿透是药物研发的关键挑战，此次合作将利用诺华在神经科学领域的专长开发下一代疗法。神经科学是诺华的四大重点治疗领域之一，与肿瘤学、免疫学及心血管、肾脏和代谢疾病并列。阿斯利康 & JCR Pharmaceuticals美东时间7月8日，阿斯利康的罕见病部门Alexion，与现有合作伙伴JCR Pharmaceuticals，达成一项价值8.25亿美元的协议，以获取腺相关病毒（AAV）衣壳技术，用于开发基因组药物。根据协议，Alexion可在最多五个基因组药物项目中使用这些衣壳。JCR将获得一笔未公开的预付款，并可能收取最高2.25亿美元的里程碑付款和最高6亿美元的销售里程碑付款（前提是所有五个药物均成功上市）。此外，JCR还将获得基于净销售额的分级版税。这些衣壳源自JCR的AAV载体平台，旨在增强基因治疗的靶向递送能力，其特性包括避免肝脏或直接靶向肌肉或大脑。JCR首席执行官Shin Ashida在声明中表示，该协议基于其专有平台JUST-AAV，有望推动罕见病基因治疗的发展。阿斯利康与JCR的合作始于2023年3月，最初聚焦于潜在的血脑屏障穿透型神经退行性疾病疗法；2023年底，双方扩展合作至寡核苷酸疗法研发。2023年7月，Alexion还从辉瑞收购了多项临床前基因治疗资产，作为其2022年收购基因组药物公司LogicBio后的补充。默沙东 & erona Pharma美东时间7月9日，默沙东以100亿美元收购Verona Pharma，以获得其已上市的慢性阻塞性肺病（COPD）药物Ohtuvayre，旨在扩充呼吸道管线并应对Keytruda专利到期后的收入损失。根据协议，默沙东将以每股107美元的价格收购Verona的美国存托股票（每股代表八股普通股），总交易价值约100亿美元。双方董事会已一致批准该交易，预计于2024年第四季度完成，需满足反垄断和监管审批等条件。此次收购是2024年第二大并购交易，仅次于强生1月对Intra-Cellular的收购。Ohtuvayre于2023年6月获FDA批准作为COPD维持治疗药物；2024年第一季度，Verona估计其处方量约2.5万份，销售额达7130万美元。2025年预计销售额约4亿美元，峰值销售额或达34亿美元。Ohtuvayre将强化默沙东的呼吸道产品组合，后者近期还获批呼吸道合胞病毒抗体药物Enflonsia。在Keytruda核心专利2028年到期前，默沙东近年持续进行收购：2023年4月以108亿美元收购Prometheus Biosciences（获得炎症和免疫疾病管线）；2021年9月以110亿美元收购罕见病公司Acceleron Pharma；2022年11月以13.6亿美元收购Imago Biosciences（针对骨髓恶性肿瘤）；2023年5月以最高30亿美元收购EyeBio（重返眼科领域）。来源：Being科学","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2550464047","isCrawlerRequest":true}